Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Share-based Compensation: 2020-2024

Historic Share-based Compensation for Oncology Institute (TOI) over the last 5 years, with FY2024 value amounting to $11.2 million.

  • Oncology Institute's Share-based Compensation fell 5713.69% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 million, marking a year-over-year decrease of 6636.56%. This contributed to the annual value of $11.2 million for FY2024, which is 3738.35% down from last year.
  • Latest data reveals that Oncology Institute reported Share-based Compensation of $11.2 million as of FY2024, which was down 3738.35% from $17.8 million recorded in FY2023.
  • Oncology Institute's 5-year Share-based Compensation high stood at $27.7 million for FY2022, and its period low was $151000.0 during FY2020.
  • In the last 5 years, Oncology Institute's Share-based Compensation had a median value of $17.8 million in 2023 and averaged $16.3 million.
  • As far as peak fluctuations go, Oncology Institute's Share-based Compensation soared by 1614834.44% in 2021, and later plummeted by 3738.35% in 2024.
  • Oncology Institute's Share-based Compensation (Annual) stood at $151000.0 in 2020, then skyrocketed by 16148.34% to $24.5 million in 2021, then grew by 12.83% to $27.7 million in 2022, then tumbled by 35.66% to $17.8 million in 2023, then plummeted by 37.38% to $11.2 million in 2024.
  • Its Share-based Compensation stands at $11.2 million for FY2024, versus $17.8 million for FY2023 and $27.7 million for FY2022.